PURPOSE: To evaluate the safety and possible efficacy of subconjunctival sirolimus for the treatment of chronic active anterior uveitis. DESIGN: Prospective, nonrandomized, open-label clinical trial. METHODS: This single-center pilot trial enrolled 5 patients with chronic active anterior uveitis. The study drug was administered as a single subconjunctival injection of 30 μL (1320 μg) sirolimus in the study eye at the baseline visit. Study visits were performed at baseline, at 2 weeks, at 4 weeks, and monthly until 4 months, and included a complete ophthalmic examination, review of systems, adverse event assessment at each visit, physical examination, and ancillary ophthalmic testing at some visits. The primary outcome measure was a 2-step reduction in the anterior chamber inflammation within 4 weeks of injection of the study drug. RESULTS: There were 3 female and 2 male patients; 4 patients had idiopathic anterior uveitis and 1 had psoriatic arthritis-associated anterior uveitis. Three of the 5 patients met the primary outcome criteria by showing at least a 2-step decrease in inflammation within 4 weeks; 2 patients showed a 1-step decrease in inflammation within the same time frame. No recurrence was encountered during a 4-month follow-up. There were no serious adverse events. CONCLUSIONS: Subconjunctival sirolimus appears to be well tolerated in this pilot trial and shows promise as a treatment for active inflammation in patients with chronic anterior uveitis. Larger studies are needed to assess its usefulness in uveitis. Published by Elsevier Inc.
PURPOSE: To evaluate the safety and possible efficacy of subconjunctival sirolimus for the treatment of chronic active anterior uveitis. DESIGN: Prospective, nonrandomized, open-label clinical trial. METHODS: This single-center pilot trial enrolled 5 patients with chronic active anterior uveitis. The study drug was administered as a single subconjunctival injection of 30 μL (1320 μg) sirolimus in the study eye at the baseline visit. Study visits were performed at baseline, at 2 weeks, at 4 weeks, and monthly until 4 months, and included a complete ophthalmic examination, review of systems, adverse event assessment at each visit, physical examination, and ancillary ophthalmic testing at some visits. The primary outcome measure was a 2-step reduction in the anterior chamber inflammation within 4 weeks of injection of the study drug. RESULTS: There were 3 female and 2 male patients; 4 patients had idiopathic anterior uveitis and 1 had psoriatic arthritis-associated anterior uveitis. Three of the 5 patients met the primary outcome criteria by showing at least a 2-step decrease in inflammation within 4 weeks; 2 patients showed a 1-step decrease in inflammation within the same time frame. No recurrence was encountered during a 4-month follow-up. There were no serious adverse events. CONCLUSIONS: Subconjunctival sirolimus appears to be well tolerated in this pilot trial and shows promise as a treatment for active inflammation in patients with chronic anterior uveitis. Larger studies are needed to assess its usefulness in uveitis. Published by Elsevier Inc.
Authors: Nadine S Dejneka; Akiko M Kuroki; Joshua Fosnot; Waixing Tang; Michael J Tolentino; Jean Bennett Journal: Mol Vis Date: 2004-12-22 Impact factor: 2.367
Authors: Nirali Bhatt; Monica Dalal; William Tucker; Dominic Obiyor; Robert Nussenblatt; H Nida Sen Journal: Am J Ophthalmol Date: 2014-12-17 Impact factor: 5.258
Authors: Philip A Petrou; Denise Cunningham; Katherine Shimel; Molly Harrington; Keri Hammel; Catherine A Cukras; Frederick L Ferris; Emily Y Chew; Wai T Wong Journal: Invest Ophthalmol Vis Sci Date: 2014-12-18 Impact factor: 4.799
Authors: Mohamed A Ibrahim; Yasir J Sepah; Anthony Watters; Millena Bittencourt; Erin M Vigil; Diana V Do; Quan Dong Nguyen Journal: Transl Vis Sci Technol Date: 2015-03-10 Impact factor: 3.283